stockrowGSK PLC Sponsored ADR
GSK Healthcare Drug Manufacturers General
GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024.
- Revenue
- +3.75%
- EPS
- −14.7%
- Free cash flow
- +62.4%
- Total debt
- +33.2%
Quarter to September 2026, against a year earlier
Follow GSK
Alert me
GSK PLC Sponsored ADR (GSK) Net income
GSK PLC Sponsored ADR's net income for fiscal 2025 was $8.3B, up 119.9% from $3.8B in fiscal 2024. Over the twelve months to 30 September 2026 it was $6.3B. Over the past ten years it has ranged from $1.4B (fiscal 2016) to $12.8B (fiscal 2015); the current reading is higher than 91% of that period. GSK PLC Sponsored ADR ranks 9th of 21 Drug Manufacturers General companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $8.3B | 119.92% |
| FY2024 | $3.8B | (42.89%) |
| FY2023 | $6.6B | 8.47% |
| FY2022 | $6.1B | (13.14%) |
| FY2021 | $7.0B | (14.57%) |
| FY2020 | $8.2B | 21.93% |
| FY2019 | $6.7B | 24.55% |
| FY2018 | $5.4B | 93.20% |
| FY2017 | $2.8B | 94.22% |
| FY2016 | $1.4B | (88.76%) |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $2.3B | 213.70% |
| Jun 2026 | $732.3M | (70.45%) |
| Mar 2026 | $2.5B | 211.20% |
| Dec 2025 | $796.3M | (72.84%) |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| NVO Novo Nordisk A/S compare | $17.9B |
| AZN AstraZeneca PLC compare | $13.3B |
| AMGN Amgen Inc. compare | $9.4B |
| BMY Bristol Myers Squibb Company compare | $9.2B |
| GSK GSK PLC Sponsored ADR | $6.3B |
| SNY Sanofi compare | $4.5B |
| PFE Pfizer Inc. compare | $4.1B |
| BIIB Biogen Inc. compare | $347.5M |
| GILD Gilead Sciences, Inc. compare | −$3.9B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on GSK
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement